Inflammation and inflammatory cells in myocardial infarction and reperfusion injury: A double-edged sword

Clinical Medicine Insights: Cardiology

Volumn 10, Issue , 2016, Pages 79-84

  Liu, Jiaqi ^a,b   Wang, Haijuan ^a   Li, Jun ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Macrophage; Myocardial infarction; Reperfusion injury; Toll like receptor

Indexed keywords

CHEMOKINE RECEPTOR CCR2; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; HEALING; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; NONHUMAN; REPERFUSION INJURY; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 84976286308     PISSN: None     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S33164     Document Type: Article

References (63)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007; 357(11):1121-35.
2. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65:1454-71.
3. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010;121(22):2437-45.
4. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339(6116):161-6.
5. Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res. 2012;110(1):126-44.
6. Coggins M, Rosenzweig A. The fire within: cardiac inflammatory signaling in health and disease. Circ Res. 2012;110(1):116-25.
7. Hayashidani S, Tsutsui H, Shiomi T, et al. Anti-mcp-1 gene therapy attenuates left ventricular remodeling and failure after experimental MI. Circulation. 2003;108(17):2134-40.
8. Kaikita K, Hayasaki T, Okuma T, Kuziel WA, Ogawa H, Takeya M. Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am J Pathol. 2004;165(2):439-47.
9. Dewald O, Zymek P, Winkelmann K, et al. CCL2/MCP-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res. 2005;96(8):881-9.
10. Frangogiannis NG, Dewald O, Xia Y, et al. Critical role of MCP-1 in the pathogenesis of ischemic cardiomyopathy. Circulation. 2007;115:584-92.
11. Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 2011;29(11):1005-10.
12. Liehn EA, Piccinini AM, Koenen RR, et al. A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J Am Coll Cardiol. 2010;56(22): 1847-57.
13. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110(1):159-73.
14. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204(12):3037-47.
15. Maekawa Y, Mizue N, Chan A, et al. Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling: a regulator of bone marrow-derived dendritic cells. Circulation. 2009;120(14):1401-14.
16. Anzai A, Anzai T, Nagai S, et al. Regulatory role of DCs in postinfarction healing and left ventricular remodeling. Circulation. 2012;125(10):1234-45.
17. Hofmann U, Beyersdorf N, Weirather J, et al. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation. 2012;125(13):1652-63.
18. Eltzschig HK, Eckle T. Ischemia and reperfusion - from mechanism to translation. Nat Med. 2011;17(11):1391-401.
19. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and post-myocardial infarction remodeling. Circ Res. 2004;94(12):1543-53.
20. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res. 2008;58(2):88-111.
21. Weinberger T, Schulz C. Myocardial infarction: a critical role of macrophages in cardiac remodeling. Front Physiol. 2015;6:107.
22. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566): 301-5.
23. Marty RR, Dirnhofer S, Mauermann N, et al. MyD88 signaling controls autoimmune myocarditis induction. Circulation. 2006;113(2):258-65.
24. Shishido T, Nozaki N, Yamaguchi S, et al. TLR2 modulates ventricular remodeling after myocardial infarction. Circulation. 2003;108(23):2905-10.
25. Valeur HS, Valen G. Innate immunity and myocardial adaptation to ischemia. Basic Res Cardiol. 2009;104(1):22-32.
26. Frantz S, Kobzik L, Kim YD, et al. TLR4 expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104(3):271-80.
27. Akira S, Takeda K. TLR signaling. Nat Rev Immunol. 2004;4(7):499-511.
28. Oyama J, Blais C Jr, Liu X, et al. Reduced myocardial ischemia-reperfusion injury in TLR4-deficient mice. Circulation. 2004;109(6):784-9.
29. Sakata Y, Dong JW, Vallejo JG, et al. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;292(1):H503-9.
30. Favre J, Musette P, Douin-Echinard V, et al. TLR2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2007;27(5):1064-71.
31. Arslan F, Smeets MB, O’Neill LA, et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation. 2010;121(1):80-90.
32. Timmers L, Sluijter JP, van Keulen JK, et al. TLR4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res. 2008;102(2):257-64.
33. Maisel A, Cesario D, Baird S, Rehman J, Haghighi P, Carter S. Experimental autoimmune myocarditis produced by adoptive transfer of splenocytes after myocardial infarction. Circ Res. 1998;82(4):458-63.
34. Moraru M, Roth A, Keren G, George J. Cellular autoimmunity to cardiac myosin in patients with a recent myocardial infarction. Int J Cardiol. 2006;107(1):61-6.
35. Zhang P, Cox CJ, Alvarez KM, Cunningham MW. Cutting edge: cardiac myosin activates innate immune responses through TLRs. J Immunol. 2009;183(1):27-31.
36. Eriksson S, Hellman J, Pettersson K. Autoantibodies against cardiac troponins. N Engl J Med. 2005;352(1):98-100.
37. Göser S, Andrassy M, Buss SJ, et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation. 2006;114(16):1693-702.
38. Varda-Bloom N, Leor J, Ohad DG, et al. Cytotoxic T lymphocytes are activated following myocardial infarction and can recognize and kill healthy myocytes in vitro. J Mol Cell Cardiol. 2000;32(12):2141-9.
39. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost. 2007;97(5):738-47.
40. White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation - therapeutic opportunities and pharmacological challenges. Pharmacol Rev. 2013;65(1):47-89.
41. Kumar AG, Ballantyne CM, Michael LH, et al. Induction of MCP-1 in the small veins of the ischemic and reperfused canine myocardium. Circulation. 1997;95(3): 693-700.
42. Behr TM, Wang X, Aiyar N, et al. MCP-1 is upregulated in rats with volume: overload congestive heart failure. Circulation. 2000;102(11):1315-22.
43. Aukrust P, Ueland T, Müller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. 1998;97(12):1136-43.
44. Zhou L, Azfer A, Niu J, et al. MCP-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res. 2006;98(9): 1177-85.
45. Yamamoto T, Eckes B, Mauch C, et al. MCP-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol. 2000;164(12):6174-9.
46. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and TGF-beta1 gene expression by MCP-1 via specific receptors. J Biol Chem. 1996;271(30):17779-84.
47. Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int J Cardiol. 2008;130(2):147-58.
48. Frantz S, Nahrendorf M. Cardiac macrophages and their role in ischaemic heart diseases. Cardiovasc Res. 2014;102(2):240-8.
49. Fujiu K, Wang J, Nagai R. Cardioprotective function of cardiac macrophages. Cardiovasc Res. 2014;102(2):232-9.
50. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953-64.
51. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958-69.
52. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723-37.
53. Epelman S, Lavine KJ, Beaudin AE, et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity. 2014;40(1):91-104.
54. Courties G, Heidt T, Sebas M, et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J Am Coll Cardiol. 2014;63(15):1556-66.
55. Hilgendorf I, Gerhardt LM, Tan TC, et al. Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium. Circ Res. 2014;114(10):1611-22.
56. Ben-Mordechai T, Holbova R, Landa-Rouben N, et al. Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. J Am Coll Cardiol. 2013;62:1890-901.
57. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
58. Zhang J, Yu ZX, Fujita S, Yamaguchi ML, Ferrans VJ. Interstitial dendritic cells of the rat heart: quantitative and ultrastructural changes in experimental myocardial infarction. Circulation. 1993;87(3):909-20.
59. Naito K, Anzai T, Sugano Y, et al. Differential effects of GM-CSF and G-CSF on infiltration of dendritic cells during early left ventricular remodeling after myocardial infarction. J Immunol. 2008;181(8):5691-701.
60. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH. Dendritic cell induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med. 2003;9(12):1484-90.
61. Yang Z, Day YJ, Toufektsian MC, et al. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation. 2006;114(19):2056-64.
62. Weirather J, Hofmann UD, Beyersdorf N, et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res. 2014;115(1):55-67.
63. Zouggari Y, Ait-Oufella H, Bonnin P, et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med. 2013;19(10):1273-80.